LIFEMINE THERAPEUTICS - Key Persons

Job Titles:

• Member of the Board
• Vice President, Head of Microbiology & Automation

Mr. Cao Yanling is a founding member of Boyu Capital and in charge of investments and portfolio management in the healthcare sector. He currently serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Prior to Boyu, Mr. Cao worked as an investment professional at General Atlantic and Goldman Sachs on a wide range of strategic and financial transactions. Mr. Cao received a Bachelor of Arts in Economics and Mathematics, summa cum laude, from Middlebury College. Dawn Thompson is uniquely positioned to combine a deep knowledge of fundamental life science disciplines including fungal microbiology, molecular genetics, transcriptomics, comparative genomics, evolutionary biology and synthetic biology to crack the code of therapeutically relevant natural products encoded in fungal genomes. Prior to joining LifeMine, Dawn was Chief Scientific Officer at Directed Genomics where she led the scientific vision to develop novel DNA and RNA assays with a focus on Next Generation Sequencing (NGS) for research, translational, clinical, and agricultural applications. Before that, Dawn built a multi-disciplinary team from the ground up as Head of NGS at Ginkgo Bioworks that offered a diverse portfolio of sequencing applications including fully automated DNA sequencing, genome assembly, and RNA-seq. In this role, Dawn partnered with organizational leaders to solve cross-functional challenges unique to the engineering of novel organism factories to grow products by fermentation across many markets including pharmaceuticals, living medicines, agriculture and electronics. Before joining Ginkgo, Dawn was the Associate Director of the Cell Circuits Program (CCP) at the Broad Institute where she was integral to the scientific vision and technological development toward systematically defining the genetic and molecular circuits of a wide range of cell types. Concurrently, Dawn was a Group Leader in Genome Biology and directed a research program to study the evolution of gene regulation across diverse fungal species to elucidate the mechanisms underlying the evolution of new phenotypes. Dawn was a postdoctoral fellow at Harvard University where she investigated the effect of elevated mutation rate and ploidy on the rate of adaptive evolution and genome rearrangement in yeast. Dawn earned a Ph.D. in molecular biology from the University of Oregon and a B.S. in biology from the University of New Hampshire.

Job Titles:

• Member of the Board
• Physician
• Programmer

Dr. Krishna Yeshwant is a physician, programmer, entrepreneur and general partner of GV who has been working with GV (previously Google Ventures) since its inception. He first joined Google as part of the New Business Development team. Prior to Google, Dr. Yeshwant helped start an electronic data interchange company that was acquired by Hewlett-Packard and a network security company that was acquired by Symantec. Dr. Yeshwant has a B.S. in Computer Science from Stanford University. He also earned an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, and completed his residency at Brigham and Women's Hospital in Boston, Massachusetts where he continues to practice.

Job Titles:

• CMO and EVP, Translational Science

Elliot Ehrich has dedicated his career to translating scientific discoveries into new medicines for illnesses that have no effective treatments or are inadequately addressed by existing therapies. Over the course of 25+ years in pharma and biotech, he has led or directly contributed to the discovery, development, and successful registration of 8 medicines across a spectrum of therapeutic areas. Elliot joined LifeMine from Skyhawk Therapeutics, where he served as President and led research, drug discovery, and drug development activities. Prior to Skyhawk, Elliot was a Venture Partner at 5AM Ventures, a venture capital firm focused on early- stage life science companies. Elliot had previously spent 18 years at Alkermes, Inc., where he served as Executive Vice President of Research & Development and Chief Medical Officer. During his tenure, Elliot initiated a transformation of the company's R&D focus from medicines based on drug delivery technology to a diverse portfolio of novel, proprietary small molecule therapeutics. In doing so, he led the discovery, development, and, ultimately, the FDA registration of a series of medicines for multiple therapeutic indications, including schizophrenia, alcohol and opioid dependence, and multiple sclerosis. He also initiated a novel cytokine program for the treatment of malignancy, which is in ongoing phase 3 clinical development. Elliot began his industry career in the clinical pharmacology group at Merck Research Labs, where he gained extensive experience in the assessment of human pharmacokinetics and drug-exposure-response relationships. He then spent several years working in pulmonary-immunology clinical development at Merck. Elliot received a B.A. in Biochemistry from Princeton University. After graduating, he was a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. He subsequently received an M.D. from Columbia University and completed an internship and residency in internal medicine at Stanford University. After residency, Elliot continued at Stanford and completed a clinical fellowship in immunology and rheumatology followed by a Cancer Research Institute-sponsored postdoctoral fellowship in T cell biology in the laboratory of Professor Mark Davis.

Job Titles:

• Chief Executive Officer
• Leader
• Member of the Board
• President

Gregory Verdine is a leader in the discovery, development and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Greg coined the phrase "drugging the undruggable" to describe his life mission. LifeMine is the brainchild of Greg, who as a venture partner of WuXi Healthcare Ventures, led the founding team that brought the company from concept to reality. In his role as President and CEO of LifeMine, Greg is leading the company through its ramp-up and march toward the clinic. Greg is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor, and company executive. As Erving Professor at Harvard University and Harvard Medical School, he made seminal contributions to understanding mechanisms of DNA repair and epigenetic DNA methylation and he invented a new drug modality called stapled peptides. As an entrepreneur, Greg has founded multiple, public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron, and a private company, Gloucester Pharmaceuticals, that was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs. Greg has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio and FOG, Greg took a role in managing these companies as their president, chief executive officer and chief scientific officer. Greg earned his Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph's University and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.

Job Titles:

• Medical Institute Investigator

Job Titles:

• Chief Data Officer
• Scientist

Iain McFadyen is a computational scientist who combines demonstrated leadership and strategic vision with an exceptionally broad technical wingspan ranging from genomics, transcriptomics, and protein structure analysis to structure-based drug design, chemoinformatics, deep learning, and translational bioinformatics. Prior to LifeMine, Iain held positions of increasing responsibility at Moderna, Inc., where he headed up Computational Sciences and Next Generation Analytics. He built a department applying bioinformatics, computational biology, computational chemistry, non-clinical statistics, data science, and NGS to meet the needs of groups and programs across the company. Prior to Moderna, Iain led the development of a big data analytics framework to extract commodity futures trading signals from real-time global geospatial data on maritime cargo movements as an Associate Director at CargoMetrics Technologies, LLC. Before that, Iain was a Principal Research Scientist and Group Leader at TransForm Pharmaceuticals where he led a $10M Grand Challenges in Global Health grant from the Bill & Melinda Gates Foundation. Iain started his career in increasing roles of responsibility at Genetics Institute/Wyeth Research where he ultimately served as a Senior Scientist focused on rational, structure-based drug design and chemoinformatics applied to a variety of protein targets. Iain earned a Ph.D. in pharmacology from Loughborough University (UK) and the University of Michigan in the Traynor Lab and a B.S. in medicinal and pharmaceutical chemistry from Loughborough University (UK). He was a Postdoctoral Research Associate at the University of Minnesota where he focused on the structural basis of opioid receptor ligand selectivity in the Ferguson Lab.

Job Titles:

• SVP, Head of People

Jackie Donovan brings a unique blend of R&D and HR experience, allowing her to drive and evolve the LifeMine talent strategy with its pipeline strategy to scale to the clinic and beyond. Jackie joined LifeMine from Alexion Pharmaceuticals, where she served as Vice President and Head of People Operations and oversaw the HR Strategy as well as all HR Operations functions globally. During her time in this role, Jackie worked to create and deliver Alexion's Employee Experience focused HR strategy and focused on creating an unparalleled employee and customer experience in Rare Disease. Prior to that, Jackie held a variety of HR and R&D leadership and strategy roles at Alexion, Baxalta, Shire and Pfizer where she built high performing teams, created effective scientific governance, and drove effective workforce planning for programs from Proof of Concept to regulatory approval and commercialization. Jackie holds a BA from Brown University and is currently enrolled in the CHRO program at Wharton Business School at the University of Pennsylvania.

Job Titles:

• Chief Operating Officer
• Member of the Board

Jennifer Jarrett is currently chief operating officer and serves on the board of Arcus Biosciences, a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. She currently serves on the boards of Syndax Pharmaceuticals and SMART, a non-profit organization, and previously served on the boards of Arena Pharmaceuticals and Audentes Therapeutics. Jennifer previously served as vice president, corporate development and capital markets at Uber and as chief financial officer of Medivation. Prior to Medivation, Jennifer spent 20 years in investment banking, most recently at Citigroup, where she ran the firm's west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Jennifer holds a B.A. in economics from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business.

Job Titles:

• Founding Member of Boyu Capital

Job Titles:

• Member of the Board
• Co - CEO at WuXi AppTec

Mr. Edward Hu is currently the Co-CEO at WuXi AppTec. With experience in operations, financial management, capital markets, global business expansion, merger and acquisitions and venture investments, Mr. Hu has demonstrated his leadership in building and growing global businesses. Since he joined WuXi in 2007, Mr. Hu has served as the company's Chief Operating Officer, and later Chief Financial Officer and Chief Investment Officer. Over the past decade, he has scored significant achievements in WuXi's rapid development. Mr. Hu was elected to WuXi's Board of Directors in March 2016. Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. His earlier career spanned at Biogen and Merck respectively. Mr. Hu has an MBA and Master's degree in Chemistry from Carnegie Mellon University.

Job Titles:

• Chairman of the Board
• Co - Founder
• Founder and Chief Scientist of Altos Labs

Dr. Klausner is currently founder and Chief Scientist of Altos Labs and founder and Chairman of Lyell Immunopharma, Inc. He is President of the Milky Way Research Foundation and founder and Managing Partner of Milky Way Investments. He was founder and Director of Juno Therapeutics and founder and Director of GRAIL. He is Chairman of Sonoma Biotherapeutics. Co-Founder and Chairman of Lifemine Therapeutics. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. Previously, he was Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation. He has served in senior advisory roles to the US, Norwegian, Qatari and Indian governments. More specific to his own research accomplishments, Dr. Klausner has provided valuable mechanistic insights into cellular processes such as intracellular trafficking, translation, and protein assembly. He has also contributed to the understanding of posttranslational gene regulation mechanisms through his study of iron metabolism. Furthermore, his investigations into the von Hippel-Lindau (VHL) protein has led to further classification of the protein's tumor suppressive function in the context of renal cell carcinoma. His discovery of the T Cell Zeta chain and how T cells are activated was the basic science breakthrough that lead to successful cell-based CAR-T cancer therapy. Throughout his career, Dr. Klausner has consistently worked to apply the principles of science and technology to address the global cancer burden. Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees and other honors. He has served as an Advisor to the Presidents of the Academies for counterterrorism, and Liaison to the White House Office of Science & Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for US Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Job Titles:

• Leader
• EVP, Head of
• Head of Genomics, Multiomics & AI

Roberto Olivares-Amaya is a leader in scientific computing with 10 years of experience at the interface of machine learning and software development for life sciences and healthcare. His experience spans computational chemistry, bioinformatics, and medical informatics. Roberto is Head of Genomics, Multiomics & AI at LifeMine. His role is to lead the effort across the company to deploy machine learning toward the discovery of naturally sourced precision medicine. Most recently, Roberto was VP of AI Engineering at ConcertAI. He built a strong team of machine learning and data engineers that developed an NLP-based knowledge graph for EHR ontologies, and deep learning methods for outlier detection. Prior to that, Roberto was VP of Technology at GNS Healthcare. His team was responsible for delivering GNS's causal ML platform, called REFS. His team also worked on the development of methods to find prognostic and predictive biomarkers in gene networks using multi-omics data. Roberto started his career as one of the first employees at ArcBio, a startup in the metagenomics diagnostics space, where he created novel methods of genome compression, alignment, variant calling, and pathogen identification. As a co-founder of "Clubes de Ciencia Mexico" an organization that offers extracurricular STEM education, Roberto is helping to promote science education. The program has expanded to multiple countries in Latin America. Roberto was a postdoctoral fellow at Princeton University where he explored theoretical chemistry methods, their limits and to make them accessible to chemists. Roberto earned a Ph.D. in chemical physics from Harvard University with his research at the interface of computational chemistry and machine learning, and a B.Sc. in chemistry from the National Autonomous University of Mexico (UNAM). Louis Plamondon is a recognized leader in the discovery, development and commercialization of small molecule drugs. He is a passionate scientist with experience leading multidisciplinary teams and overseeing programs across several therapeutic areas and development stages. Prior to joining LifeMine, Louis was SVP and Head of CMC at Constellation Pharmaceuticals (a MorphoSys company) where he led all pre-development/development activities including production of Drug Substance and Drug Product for pre-clinical studies, toxicology studies, clinical studies, and preparations for commercialization. His expertise ranges from enabling Phase I studies through global registrational application and includes commercial manufacturing and launch activities. His impressive influence includes establishing clinical and commercial supply chain strategies, vendor and alliance management, portfolio strategy implementation, developing regulatory strategies, negotiating with global health authorities, developing life-cycle management strategies and generating secondary patents to extend product life-cycle. Some of his key contributions include being a co-inventor and leader for Velcade® (bortezomib), the first proteasome inhibitor approved for the treatment of patients with multiple myeloma, and co-inventor for Xerava® (Eravacycline), the first fully synthetic fluorocycline used for the treatment of complicated intra-abdominal infections (cIAI). Louis earned his Ph.D. in Organic Chemistry from the Université de Montréal under the guidance of James D. Wuest and completed his postdoctoral fellowship at Harvard University under the guidance of Stuart L. Schreiber.

Job Titles:

• Scientist
• VP, Biology

Sheila is a passionate scientist who is experienced in all parts of the drug discovery process from target ID and validation to the clinic. She is a drug discovery professional who has taken a modality agnostic approach to targets throughout her career, progressing antibodies, small molecules and engineered protein therapeutics to candidate selection and preclinical development. Prior to joining LifeMine, Sheila was Director, Discovery Oncology at Merck. During this time, she built a topflight team of biologists which characterized the immunological mechanism of action of oncology drugs singly, and in combination with checkpoint inhibitors, in the tumor microenvironment, impacting nearly all projects in the Merck Discovery Oncology pipeline. In addition, Sheila led several multi-disciplinary teams to develop drug candidates including two small molecules and two engineered protein therapeutics, which are in pre-clinical development. Before joining Merck, she spent ten years in positions of increasing responsibility at Wyeth/Pfizer, Ironwood Pharmaceuticals and Enumeral Biomedical working in the Cardiovascular/Metabolic, Inflammation, and Immuno-Oncology therapeutic areas discovering antibody, peptide, and small molecule drug candidates. Sheila earned a B.A. in Molecular and Cellular Biology from U.C. Berkeley and a Ph.D in Immunology from Washington University with Professor Kenneth Murphy. She was a postdoctoral fellow at Harvard Medical School where she investigated the mechanisms of VDJ Recombination and Non-Homologous End Joining in lymphomagenesis with Professor Frederick Alt.

Job Titles:

• Leader
• VP, Synthetic Biology, Bioengineering, and Bioprocess

Tom Ramseier is a senior biotechnology leader who brings tremendous leadership experience in developing and executing R&D programs to advance biotech products from concept to commercial success. Most recently, Tom founded Ramseier Biotech Consulting where he provided expert solutions ranging from Metabolic Engineering and Synthetic Biology to Technology Due Diligence, IP/FTO analysis, and Regulatory Affairs. Prior to founding Ramseier Biotech Consulting, Tom worked at Dow Agrosciences as the Microbial Strain Engineering Leader where he directed multi-functional teams to genetically engineer recalcitrant microbes for the advantaged manufacture of high-value secondary metabolites. Prior to this, Tom was Director of Microbial Development at Metabolix, where he strategically led R&D teams to develop robust industrial strains for the commercial manufacture of bioplastics and industrial chemicals from renewable resources. Additionally, Tom was R&D Leader of the Molecular and Systems Biology Department at Dow Chemical, where he led specialists to deliver a novel production platform for industrial and pharmaceutical proteins. He also held positions at Monsanto, Mitsubishi Petrochemical, and UC San Diego. He is an inventor of 20 patent families and has authored numerous peer-reviewed research articles. Tom earned his Ph.D. in Natural Sciences from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland.

Job Titles:

• Member of the Board
• Sidney Farber Professor

William Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women's Hospital and Harvard Medical School. He obtained his undergraduate and M.D. degrees from Duke University and completed his training in internal medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in medical oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow in David Livingston's laboratory, during which time he was a McDonnell Scholar. A Nobel laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society of Clinical Investigation, and the American College of Physicians. He previously served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center; the Richard and Hinda Rosenthal Prize from the AACR; a Doris Duke Distinguished Clinical Scientist award; the 2010 Canada International Gairdner Award; ASCI's Stanley J. Korsmeyer Award; the Scientific Grand Prix of the Foundation Lefoulon-Delalande; the Wiley Prize in Biomedical Sciences; the Steven C. Beering Award; the AACR Princess Takamatsu Award; the ASCO Science of Oncology Award; the Helis Award; the Albert Lasker Basic Medical Research Prize; and the Massry Prize. A Howard Hughes Medical Institute Investigator since 1998, Dr. Kaelin's research seeks to understand how, mechanistically, mutations affecting tumor suppressor proteins cause cancer. His laboratory is currently focused on studies of the VHL and RB tumor suppressor proteins. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins. His work on the VHL protein helped to motivate the eventual successful clinical testing of VEGF inhibitors for the treatment of kidney cancer and the recent testing of HIF2 inhibitors for this disease. Moreover, this line of investigation led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as anemia, myocardial infarction, and stroke. His group also showed that leukemic transformation by mutant IDH was reversible, setting the stage for the development and approval of mutant IDH inhibitors, and discovered how thalidomide-like drugs kill myeloma cells by degrading two otherwise undruggable transcription factors. He is currently trying to exploit this later paradigm to target other undruggable oncoproteins.